BD FastImmune™ Antibody Cocktail (IFN-γ FITC, CD69 PE, CD8 PerCP-Cy™5.5, CD3 APC)

Anti-Hu–IFN-γ, clone 25723.11, is derived from the hybridization of P3X-63-Ag8.653 mouse myeloma cells with lymph node cells from BALB/c mice immunized with recombinant human IFN-γ.

CD69, clone L78, is derived from hybridization of Sp2/0-Ag14 mouse myeloma cells with lymph node cells from BALB/c mice immunized with a CD8⁺ alloantigen-directed cytotoxic T-lymphocyte (CTL) cell line.

CD8, clone SK1, is derived from hybridization of NS-1 mouse myeloma cells with spleen cells from BALB/c mice immunized with human peripheral blood T lymphocytes.

CD3, clone SK743-46, is derived from hybridization of NS-1 mouse myeloma cells with spleen cells from BALB/c mice immunized with human thymocytes.

Anti-Human Interferon-γ (Anti-Hu–IFN-γ) recognizes a 20- to 25-kilodalton (kDa) glycoprotein.

The CD69 antibody recognizes a very early human activation antigen. The CD69 antigen is a surface homodimer formed by the association of 28-kDa and 32-kDa chains that are held together by disulfide bridges.

The CD8 antibody recognizes an antigen expressed on the 32-kilodalton (kDa) α subunit of a disulfide-linked bimolecular complex. The cytoplasmic domain of the α subunit of the CD8 antigen is associated with the protein tyrosine kinase p56^lck.

The CD8 molecule interacts with class I major histocompatibility complex (MHC) molecules resulting in increased adhesion between the CD8⁺ T lymphocytes and the target cells. Binding of the CD8 molecule to class I MHC molecules enhances the activation of resting T lymphocytes.

The CD3 antibody reacts with the epsilon chain of the CD3 antigen/T-cell antigen receptor (TCR) complex. The antigen recognized by CD3 antibodies is noncovalently associated with either α/β or γ/δ TCR (70 to 90 kDa).